FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740491863> ?p ?o ?g. }

• W2740491863 abstract "Epigenetic changes in cancer are thought to contribute to regulation of invasion and metastasis. To study this at a genome-wide level in melanoma we analyzed the methylome of 44 cases of malignant melanoma. We saw widespread demethylation in melanoma occurring preferentially outside of CpG islands. Comparison of primary and metastatic lesions showed demethylation occurs early during carcinogenesis with few additional alterations in advanced tumors. The colony stimulating factor-1 receptor was aberrantly expressed and hypomethylated in nearly all cases. The expression of CSF1R was validated by IHC on primary tumors and by qPCR and Western blotting in BRAF mutant and WT cell lines. CSF1R can be aberrantly expressed via an upstream LTR element in Hodgkin’s lymphoma. After analyzing our patient samples and the cell lines, we have found this aberrant transcript may be the dominant form in melanoma as well. Expression of one of its ligands IL34 was also shown in the cell lines by both ELISA and qPCR pointing to a potential autocrine regulatory loop. The effects of a small molecule inhibitor, PLX3397 as well as shRNA-mediated knockdown of the receptor were investigated in 2D and 3D cell culture. We saw inhibition of cell growth, smaller colony size, increased apoptosis and decreased invasiveness - suggesting a functional role for CSF1R in melanoma. Treatment of melanoma with small molecule inhibitors of BRAF V600E is effective for a time, but resistance invariably develops. The feedback activation of EGFR, BRAF amplification, BRAF splice variants and others are known to aid in the acquisition of resistance and the rebound activation of the MAPK-pathway. We are suggesting a role for CSF1R in this process. In Western experiments, the rebound of phospho-ERK after BRAF inhibitor treatment was accelerated with the addition of CSF1R ligands, or delayed with PLX3397, also attenuating AKT phosphorylation. Melanoma cells stably expressing shRNA against CSF1R recapitulated the effects of the inhibitor. Assaying the cells at different time points during a long-term V600E inhibitory experiment, we saw increasing levels of the transcription factor RUNX1, followed by increasing levels of IL34 and of the receptor, as well as its maturation, evidenced by the appearance of the high MW form. Utilizing shRNA-mediated knockdown of RUNX1 resulted in lower levels of the CSF1R and IL34 transcripts and delayed the rebound. Analysis of primary RNA-Seq data showed an increase in RUNX1, CSF1R and IL34 expression in resistant tumors. Co-inhibition of CSF1R and BRAF was also tested and resulted in synergistic blockade of cell growth in vitro and xenograft growth in vivo. The CSF1R inhibitor, PLX3397 is currently in clinical trials for glioblastoma, prostate, breast cancers and other cancers. These data present a preclinical rationale for its study in malignant melanoma. Citation Format: Orsolya Giricz, Yongkai Mo, Caroline Y. Hu, Yiting Yu, Kith Pradhan, Matthias Bartenstein, Nandini Ramachandra, Veronika Polishchuck, Kimberly B. Dahlman, Tushar Bhagat, Hoa Nguyen, Bernice Matusow, Rafe Shellooe, Elizabeth Burton, Paraic Kenny, John Greally, Jeffrey Sosman, Gideon Bollag, Brian West, Amit Verma. Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and the acquisition of resistance against BRAF inhibition [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3332. doi:10.1158/1538-7445.AM2017-3332" @default.
• W2740491863 created "2017-08-08" @default.
• W2740491863 creator A5007922486 @default.
• W2740491863 creator A5010123075 @default.
• W2740491863 creator A5012060942 @default.
• W2740491863 creator A5012812748 @default.
• W2740491863 creator A5018155158 @default.
• W2740491863 creator A5028821571 @default.
• W2740491863 creator A5034322595 @default.
• W2740491863 creator A5039886481 @default.
• W2740491863 creator A5046499856 @default.
• W2740491863 creator A5048839844 @default.
• W2740491863 creator A5049323646 @default.
• W2740491863 creator A5053723355 @default.
• W2740491863 creator A5056428008 @default.
• W2740491863 creator A5068747459 @default.
• W2740491863 creator A5069230508 @default.
• W2740491863 creator A5071785832 @default.
• W2740491863 creator A5071909219 @default.
• W2740491863 creator A5075503564 @default.
• W2740491863 creator A5075566772 @default.
• W2740491863 creator A5085858912 @default.
• W2740491863 date "2017-07-01" @default.
• W2740491863 modified "2023-10-15" @default.
• W2740491863 title "Abstract 3332: Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and the acquisition of resistance against BRAF inhibition" @default.
• W2740491863 doi "https://doi.org/10.1158/1538-7445.am2017-3332" @default.
• W2740491863 hasPublicationYear "2017" @default.
• W2740491863 type Work @default.
• W2740491863 sameAs 2740491863 @default.
• W2740491863 citedByCount "0" @default.
• W2740491863 crossrefType "proceedings-article" @default.
• W2740491863 hasAuthorship W2740491863A5007922486 @default.
• W2740491863 hasAuthorship W2740491863A5010123075 @default.
• W2740491863 hasAuthorship W2740491863A5012060942 @default.
• W2740491863 hasAuthorship W2740491863A5012812748 @default.
• W2740491863 hasAuthorship W2740491863A5018155158 @default.
• W2740491863 hasAuthorship W2740491863A5028821571 @default.
• W2740491863 hasAuthorship W2740491863A5034322595 @default.
• W2740491863 hasAuthorship W2740491863A5039886481 @default.
• W2740491863 hasAuthorship W2740491863A5046499856 @default.
• W2740491863 hasAuthorship W2740491863A5048839844 @default.
• W2740491863 hasAuthorship W2740491863A5049323646 @default.
• W2740491863 hasAuthorship W2740491863A5053723355 @default.
• W2740491863 hasAuthorship W2740491863A5056428008 @default.
• W2740491863 hasAuthorship W2740491863A5068747459 @default.
• W2740491863 hasAuthorship W2740491863A5069230508 @default.
• W2740491863 hasAuthorship W2740491863A5071785832 @default.
• W2740491863 hasAuthorship W2740491863A5071909219 @default.
• W2740491863 hasAuthorship W2740491863A5075503564 @default.
• W2740491863 hasAuthorship W2740491863A5075566772 @default.
• W2740491863 hasAuthorship W2740491863A5085858912 @default.
• W2740491863 hasConcept C121608353 @default.
• W2740491863 hasConcept C128240485 @default.
• W2740491863 hasConcept C173396325 @default.
• W2740491863 hasConcept C2777658100 @default.
• W2740491863 hasConcept C2779013556 @default.
• W2740491863 hasConcept C2781018059 @default.
• W2740491863 hasConcept C29537977 @default.
• W2740491863 hasConcept C502942594 @default.
• W2740491863 hasConcept C54355233 @default.
• W2740491863 hasConcept C555283112 @default.
• W2740491863 hasConcept C81885089 @default.
• W2740491863 hasConcept C86803240 @default.
• W2740491863 hasConceptScore W2740491863C121608353 @default.
• W2740491863 hasConceptScore W2740491863C128240485 @default.
• W2740491863 hasConceptScore W2740491863C173396325 @default.
• W2740491863 hasConceptScore W2740491863C2777658100 @default.
• W2740491863 hasConceptScore W2740491863C2779013556 @default.
• W2740491863 hasConceptScore W2740491863C2781018059 @default.
• W2740491863 hasConceptScore W2740491863C29537977 @default.
• W2740491863 hasConceptScore W2740491863C502942594 @default.
• W2740491863 hasConceptScore W2740491863C54355233 @default.
• W2740491863 hasConceptScore W2740491863C555283112 @default.
• W2740491863 hasConceptScore W2740491863C81885089 @default.
• W2740491863 hasConceptScore W2740491863C86803240 @default.
• W2740491863 hasLocation W27404918631 @default.
• W2740491863 hasOpenAccess W2740491863 @default.
• W2740491863 hasPrimaryLocation W27404918631 @default.
• W2740491863 hasRelatedWork W1054558676 @default.
• W2740491863 hasRelatedWork W1506924747 @default.
• W2740491863 hasRelatedWork W1801698032 @default.
• W2740491863 hasRelatedWork W1988667427 @default.
• W2740491863 hasRelatedWork W2023232785 @default.
• W2740491863 hasRelatedWork W2079568117 @default.
• W2740491863 hasRelatedWork W2116629325 @default.
• W2740491863 hasRelatedWork W2141116320 @default.
• W2740491863 hasRelatedWork W2265145264 @default.
• W2740491863 hasRelatedWork W2482788363 @default.
• W2740491863 hasRelatedWork W2597626829 @default.
• W2740491863 hasRelatedWork W2886311293 @default.
• W2740491863 hasRelatedWork W2886364267 @default.
• W2740491863 hasRelatedWork W2892425221 @default.
• W2740491863 hasRelatedWork W2901133680 @default.
• W2740491863 hasRelatedWork W2982255111 @default.
• W2740491863 hasRelatedWork W3004491023 @default.
• W2740491863 hasRelatedWork W3090707051 @default.
• W2740491863 hasRelatedWork W3091542539 @default.
• W2740491863 hasRelatedWork W3178919840 @default.
• W2740491863 isParatext "false" @default.
• W2740491863 isRetracted "false" @default.

• next